Venous thromboembolism in COVID-19: A systematic review and meta-analysis

Abstract

Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous thromboembolism events (VTE). This study performed a systematic review in PubMed/EMBASE of studies reporting the prevalence of VTE in patients with COVID-19 who were totally screened/assessed for deep vein thrombosis (DVT) and/or for pulmonary embolism (PE). Among 47 candidate studies ( n = 6459; 33 in Europe), 17 studies ( n = 3973; weighted age 63.0 years, males 60%, intensive care unit (ICU) 16%) reported the prevalence of PE with a pooled estimate of 32% (95% CI: 25, 40%), and 32 studies ( n = 2552; weighted age 62.6 years, males 57%, ICU 49%) reported the prevalence of DVT with a pooled estimate of 27% (95% CI: 21, 34%). A total of 36 studies reported the use of at least prophylactic antithrombotic treatment in the majority of their patients. Meta-regression analysis showed that the prevalence of VTE was higher across studies with a higher percentage of ICU patients and higher study population mean D-dimer values, and lower in studies with mixed dosing of anticoagulation in ⩾ 50% of the population compared to studies with standard prophylactic dosing of anticoagulation in < 50% of the population. The pooled odds ratio for death in patients with COVID-19 and VTE versus those without VTE (17 studies, n = 2882) was 2.1 (95% CI: 1.2, 3.6). Hospitalized patients with severe COVID-19 are at high VTE risk despite prophylactic anticoagulation. Further research should investigate the individualized VTE risk of patients with COVID-19 and the optimal preventive antithrombotic therapy. PROSPERO Registration No.: CRD42020185543.

Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients – the BISHOP study

“…Clinically relevant PTE was estimated at 8% (95%CI, 4-11%) (27) . Notably, in critically ill patients, this prevalence is remarkably higher, with prevalences reported of up to 76% in this population (28) .…”

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic

“…Furthermore, COVID-19 has been associated with activation of the complement system as well as the development of autoantibodies in hospitalized patients; manifest autoimmune disease related to these newfound autoantibodies and complement consumption has also been observed (15)(16)(17)(18). Another feature of COVID-19, resembling SLE and antiphospholipid syndrome (APS), is the increased risk of thromboembolic events (15,19). Thereto, early in the pandemic, the use of the cornerstone drug for SLE, hydroxychloroquine (HCQ), was suggested to have antiviral effects, but current data do not support its use in COVID-19.…”

Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing

“…It might be argued that the benefit of a more aggressive strategy is obtained before the advent of critical disease and the establishment of irreversible pathology in lung vessels. Second, the rate of VTE events was 3.4% which was significantly lower compared to that reported in the literature, especially with systematic assessment/screening and in critically ill patients (ICU) [ 8 , 9 ]. As acknowledged by the authors, this might have been attributed to the lack of systematic routine screening or the underdiagnosis of less severe forms of VTE which did not translate to increased mortality [ 6 ].…”